Literature DB >> 16953832

Small hepatic nodules (< or =2 cm) in cirrhosis patients: characterization with contrast-enhanced ultrasonography.

Jing-Houng Wang1, Sheng-Nan Lu, Chao-Hung Hung, Tai-Yi Chen, Chien-Hung Chen, Chi-Sin Changchien, Chuan-Mo Lee.   

Abstract

AIM: We evaluated the efficacy of contrast-enhanced ultrasonography (CEUS) for the characterization of small hepatic nodules (< or =2 cm) in cirrhosis patients. PATIENTS AND METHODS: Thirty cirrhosis patients with 30 hepatic nodules (1-2 cm) were enrolled in this study. Eighteen hepatic nodules were hepatocellular carcinomas (HCC) and 12 were benign lesions. CEUS was performed using microbubble contrast (Levovist). With surrounding hepatic parenchyma as a reference, two characteristics of hepatic nodules, including arterial phase enhancement (AE) and the absence of delayed phase enhancement (ADE), were evaluated as criteria for the diagnosis of HCC. A radiologist independently reviewed the dynamic computed tomographies (CT) of 26 hepatic nodules.
RESULTS: CEUS showed AE in 15 nodules (13 HCC and two benign) and ADE in 17 lesions (14 HCC and three benign). For HCC, the coincidental AE of both CEUS and dynamic CT was 40%. Using both AE and ADE for HCC diagnosis, the sensitivity, specificity, accuracy, positive predictive value and negative predictive values were 55.6%, 91.7%, 70%, 90.9% and 57.9%, respectively. When using either AE or ADE for HCC diagnosis, the same parameters were 94.4%, 66.7%, 83.3%, 81% and 88.9%, respectively. One benign hepatic nodule with both AE and ADE was diagnosed as HCC 29 months after the CEUS study.
CONCLUSIONS: A combination of characteristics of AE and ADE as determined by CEUS was highly specific for small HCCs in cirrhosis patients. Concurrent delayed phase imaging is useful in the diagnosis of small hypovascular HCCs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16953832     DOI: 10.1111/j.1478-3231.2006.01318.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  12 in total

1.  Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Lorenzo Andreana; Graziella Isgrò; Maria Pleguezuelo; Giacomo Germani; Andrew K Burroughs
Journal:  World J Hepatol       Date:  2009-10-31

2.  Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound.

Authors:  Grace Lai-Hung Wong; Hui-Xiong Xu; Xiao-Yan Xie
Journal:  World J Radiol       Date:  2009-12-31

3.  Contrast-enhanced ultrasonography for the diagnosis of small hepatocellular carcinoma: a meta-analysis and meta-regression analysis.

Authors:  Yonghua Niu; Tairi Huang; Feng Lian; Fenghua Li
Journal:  Tumour Biol       Date:  2013-06-27

Review 4.  Contrast-enhanced US for characterization of focal liver lesions: a comprehensive meta-analysis.

Authors:  Menglin Wu; Liang Li; Jiahui Wang; Yanyan Zhang; Qi Guo; Xue Li; Xuening Zhang
Journal:  Eur Radiol       Date:  2017-11-30       Impact factor: 5.315

5.  High frame-rate contrast enhanced ultrasound (HIFR-CEUS) in the characterization of small hepatic lesions in cirrhotic patients.

Authors:  F Giangregorio; M Garolfi; E Mosconi; L Ricevuti; M G Debellis; M Mendozza; C Esposito; E Vigotti; D Cadei; D Abruzzese
Journal:  J Ultrasound       Date:  2022-10-13

Review 6.  Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Mirella Fraquelli; Tin Nadarevic; Agostino Colli; Cristina Manzotti; Vanja Giljaca; Damir Miletic; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2022-09-02

7.  Evaluation of contrast-enhanced ultrasonography using perfluorobutane (Sonazoid(®)) in patients with small hepatocellular carcinoma: comparison with dynamic computed tomography.

Authors:  Miki Kan; Atsushi Hiraoka; Takahide Uehara; Satoshi Hidaka; Misa Ichiryu; Hiromasa Nakahara; Hironori Ochi; Atsushi Tanabe; Akihiro Kodama; Aki Hasebe; Yasuyuki Miyamoto; Tomoyuki Ninomiya; Masanori Abe; Yoichi Hiasa; Bunzo Matsuura; Morikazu Onji; Yuki Shinbata; Chieko Kameoka; Shigekazu Doi; Hiromi Tamura; Keizou Furuya; Kojiro Michitaka
Journal:  Oncol Lett       Date:  2010-05-01       Impact factor: 2.967

8.  Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid.

Authors:  Atsushi Hiraoka; Misa Ichiryu; Nayu Tazuya; Hironori Ochi; Atsushi Tanabe; Hiromasa Nakahara; Satoshi Hidaka; Takahide Uehara; Soichi Ichikawa; Aki Hasebe; Yasunao Miyamoto; Tomoyuki Ninomiya; Masashi Hirooka; Masanori Abe; Yoichi Hiasa; Bunzo Matsuura; Morikazu Onji; Kojiro Michitaka
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

9.  Relationship between microvessel count and post-hepatectomy survival in patients with hepatocellular carcinoma.

Authors:  Atsushi Nanashima; Toshiyuki Nakayama; Yorihisa Sumida; Takafumi Abo; Hiroaki Takeshita; Kenichirou Shibata; Shigekazu Hidaka; Terumitsu Sawai; Toru Yasutake; Takeshi Nagayasu
Journal:  World J Gastroenterol       Date:  2008-08-21       Impact factor: 5.742

10.  Diagnostic value of contrast-enhanced ultrasound in hepatocellular carcinoma: a meta-analysis with evidence from 1998 to 2016.

Authors:  Juanjuan Zhang; Yanyan Yu; Ying Li; Lunshou Wei
Journal:  Oncotarget       Date:  2017-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.